AI Reality Check
Sign in to check a valuation or an Investment Case.
Sign in4528.T
Ono Pharmaceutical Co., Ltd.
5-year outlook
For information only — not financial advice.
Values today
Bear, Base, and Bull are values today. The gap is how far today's price sits from each of them. It is not a forecast of the share price in five years.
Fair value & forward multiple
Forward P/E Value
$14.46
Main approach — Forward P/E
-99.4% margin
MarketSnap Value
$15.28
Pre-calculated + market intelligence
-99.4% margin
Fair Value Confidence: Low
Forward P/E (5Y)
2,502.60×
Price ÷ year-5 avg EPS estimate
Forward P/E Value: Headline fair value is about 0.0× the reference price — far outside the usual 12× display band. Treat as a model stress test, not a price target.
MarketSnap Value: Headline fair value is about 0.0× the reference price — far outside the usual 12× display band. Treat as a model stress test, not a price target.
Values today, versus today's price
| Scenario | Value today | Versus today's price |
|---|---|---|
| Bear | $11 | -99.57% |
| Base | $15 | -99.39% |
| Bull | $27 | -98.91% |
Bear, Base, and Bull are values today. The gap is versus today's price. It is not a five-year return, and it is not a future share price.
Gap versus today's price
Expected return through 2030
From today's price to the horizon value at the end of 2030, about 4.2 years from today.
| At the horizon | Value | Return from today's price | $10,000 invested today |
|---|---|---|---|
| Base horizon value | $22.17 | -67.66% | $88 |
| Bear at that date | Unavailable. The Bear figure above is today's value, not a price at that date. | ||
| Bull at that date | Unavailable. The Bull figure above is today's value, not a price at that date. | ||
The horizon value blends Forward P/E, Price to sales at the end of 2030, about 4.2 years from today. Today's MarketSnap Value is not that price. Bear and Bull at that date are unavailable, because those figures are today's values. The context part of MarketSnap Value has no future target and is not included.
Financial quality
Overall 75/100
- Profitability Moderate
- Balance sheet Strong
- Cash flow stability Strong
- Shareholder dilution Low
- Business predictability Medium
Cash flow stability · Strong
Operating cash flow and capital spending both rose; free cash flow remained positive.
Show OCF, CapEx and FCF
| Period end | OCF | CapEx | FCF | CapEx / OCF |
|---|---|---|---|---|
| 2024-03-31 | $0.7B | $0.0B | $0.7B | 3.6% |
| 2025-03-31 | $0.5B | $0.0B | $0.5B | 6.6% |
| 2026-03-31 | $0.9B | $0.0B | $0.8B | 4.4% |
Measures historical free-cash-flow positivity and stability, not future cash generation.
Source: Company cash-flow statements (reported) Reporting periods: 2024-03-31, 2025-03-31, 2026-03-31
Investment style fit
Best suited for
Data confidence
Log in for full outcome drivers, what must go right, what can go wrong, AI Reality Check, and personalized valuation tools.
Log in to continue
Log in to see the full 5-year outlook: drivers, risks, AI tools, and your saved valuations.
Login — it's free